Skip to search formSkip to main contentSkip to account menu

Remission Induction Therapy

Initial treatment with anticancer drugs to decrease the signs or symptoms of cancer or make them disappear.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Early Steroid Therapy in Acute Lymphoblastic Leukemia Presented with Fever
Methods: From January 1, 1989 to March 20, 2013, 28 patients diagnosed with ALL at Wonju Severance Christian hospital were… 
2011
2011
Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
2011
2011
Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience.
6593 Background: Decitabine is a cytosine nucleoside analog that is FDA-approved for previously untreated and treated patients… 
2008
2008
[Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
OBJECTIVE To study the prognostic factors for events-free survival (EFS) in children with acute non-mature B-lymphoblastic… 
2004
2004
Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
We evaluated the clinical response to low-dose etoposide in relapsed acute lymphoblastic leukemia (ALL). Of the 45 patients with… 
1997
1997
Haematopoietic cytokines in the biology and treatment of acute myeloid leukaemia.
In acute myeloid leukaemia (AML), age has a definite effect on the biology of the disease and also determines the outcome of… 
1993
1993
Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia
A 47‐year‐old woman was diagnosed with acute myelomonocytic leukemia (AMMoL) and was treated with combination chemotherapy. After… 
1967
1967
Experimental Design and Clinical Cancer Chemotherapy
There are four basic parameters for evaluating objective response to chemotherapy. These are listed on the ordinate of Fig. 1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)